WS #16347
Moderna shares have experienced a sharp decline following the apparent leak of clinical data for its cancer vaccine program. This event highlights the increasing vulnerability of biotech firms to information security breaches and data integrity issues. While isolated to Moderna, it raises broader questions about the security of intellectual property in the pharmaceutical sector.
Biotech Data Leak
Moderna shares have experienced a sharp decline following the apparent leak of clinical data for its cancer vaccine program. This event highlights the increasing vulnerability of biotech firms to information security breaches and data integrity issues. While isolated to Moderna, it raises broader questions about the security of intellectual property in the pharmaceutical sector.